The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease
Introduction : There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD). Methods : This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or mor...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publications
2012-03-01
|
| Series: | Journal of the Renin-Angiotensin-Aldosterone System |
| Online Access: | https://doi.org/10.1177/1470320311412811 |
| _version_ | 1797283001363595264 |
|---|---|
| author | Nobuo Tsuboi Tetsuya Kawamura Hideo Okonogi Takeo Ishii Tatsuo Hosoya |
| author_facet | Nobuo Tsuboi Tetsuya Kawamura Hideo Okonogi Takeo Ishii Tatsuo Hosoya |
| author_sort | Nobuo Tsuboi |
| collection | DOAJ |
| description | Introduction : There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD). Methods : This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin–angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25–50 mg/day) were investigated for 12 months. Results : Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline. Conclusion : The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors. |
| first_indexed | 2024-03-07T17:22:37Z |
| format | Article |
| id | doaj.art-e7a3eb5aac9d4d7a80117045799e1425 |
| institution | Directory Open Access Journal |
| issn | 1470-3203 1752-8976 |
| language | English |
| last_indexed | 2024-03-07T17:22:37Z |
| publishDate | 2012-03-01 |
| publisher | SAGE Publications |
| record_format | Article |
| series | Journal of the Renin-Angiotensin-Aldosterone System |
| spelling | doaj.art-e7a3eb5aac9d4d7a80117045799e14252024-03-02T19:45:37ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762012-03-011310.1177/1470320311412811The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney diseaseNobuo TsuboiTetsuya KawamuraHideo OkonogiTakeo IshiiTatsuo HosoyaIntroduction : There is still insufficient data concerning the clinical effects of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease (CKD). Methods : This study included non-diabetic CKD patients with urinary protein excretion (UPE) of 1.0 g/gCr or more in spite of long-term treatment with renin–angiotensin system (RAS) inhibitors. The clinical effects of eplerenone (25–50 mg/day) were investigated for 12 months. Results : Eplerenone treatment was associated with a 38% reduction in UPE after 12 months. There was only a slight increase in the serum potassium level. The reduction of proteinuria was observed more prominently in patients with modestly impaired renal function than in those with preserved renal function at baseline. Conclusion : The long-term administration of low-dose eplerenone was effective and safe for the treatment of non-diabetic CKD patients who showed persistent proteinuria in spite of therapy with RAS inhibitors.https://doi.org/10.1177/1470320311412811 |
| spellingShingle | Nobuo Tsuboi Tetsuya Kawamura Hideo Okonogi Takeo Ishii Tatsuo Hosoya The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease Journal of the Renin-Angiotensin-Aldosterone System |
| title | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease |
| title_full | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease |
| title_fullStr | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease |
| title_full_unstemmed | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease |
| title_short | The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease |
| title_sort | long term antiproteinuric effect of eplerenone a selective aldosterone blocker in patients with non diabetic chronic kidney disease |
| url | https://doi.org/10.1177/1470320311412811 |
| work_keys_str_mv | AT nobuotsuboi thelongtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT tetsuyakawamura thelongtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT hideookonogi thelongtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT takeoishii thelongtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT tatsuohosoya thelongtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT nobuotsuboi longtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT tetsuyakawamura longtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT hideookonogi longtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT takeoishii longtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease AT tatsuohosoya longtermantiproteinuriceffectofeplerenoneaselectivealdosteroneblockerinpatientswithnondiabeticchronickidneydisease |